Healius transforms with imaging sale, debt repayment, and special dividend

Healius Limited reported a 5.7% increase in Group revenue to A$1,344.5 million for FY 2025, with underlying EBITDA at A$239.3 million and underlying EBIT at A$17.1 million. The company completed the sale of its Lumus Imaging business for A$965 million on May 1, 2025, enabling the repayment of A$515 million in existing debt, refinancing with a new A$300 million facility, and a special dividend payment of A$299.9 million (41.3 cents per share) to shareholders in May 2025.

Pathology revenues grew 6.0% to A$1.3 billion in FY 2025, though underlying EBIT decreased by 27.2% to A$17.1 million, impacted by factors including Cyclone Alfred and inflationary pressures. The company achieved A$7.3 million in annualised cost savings in FY 2025, with an additional A$8.5 million expected in FY 2026, aligning with its T27 strategic plan to achieve high single-digit EBIT margins by June 2027.

The reported net loss for the year was A$151.2 million, a substantial improvement from the A$645.8 million loss in the prior year. This includes a non-cash goodwill impairment charge of A$495.2 million in the Pathology division.